Nextgen Biotech Company of the Artgen Biotech Group (ex Human Stem Cell Institute (HSCI, MOEX: ISKJ) received patent No. 403135 in Mexico for
OPTIMIZED NUCLEOTIDE SEQUENCE AND PHARMACEUTICAL FORMULATION BASED ON IT WITH PROLONGED EXPRESSION OF VEGF TRANSGENE.
Patent No. 403135 opens up the possibility of localizing in Mexico the production of a drug similar to Neovasculgen in action, but with a longer expression of the growth factor, making it more effective.